AbbVie Inc (#ABBV) Stock Price, Live Chart & Analysis | Trade #ABBV
Abbvie Inc is a large American drug company. It was founded in 2013 after a split of Abbott Laboratories and is headquartered in Lake Bluff, Illinois, U. S. AbbVie Inc develops, manufactures and markets drugs for various diseases: AIDS, HIV, blood cancer, hepatitis C, Parkinson's disease. AbbVie Inc shares are highly regarded by both long-term investors and traders. The company belongs to the "dividend kings": dividend payments on ABBV are growing every year. The stock is steadily growing in price which adds to its popularity.
In many ways, the ABBV rate depends on the company's ability to adapt to new market conditions: develop new drugs, expand the existing product line etc. New developments are added to the company's portfolio due to large acquisitions. AbbVie Inc acquired the Irish company Allergan Plc, the manufacturer of Botox. New product launches and various acquisitions will have a positive impact on profits and thus the ABBV price.
Before trading AbbVie Inc stocks, traders should conduct a fundamental analysis. Publications in the media, as well as global events, can seriously affect the stock price. For example, the news about the purchase of stock of ABBV by Berkshire Hathaway is able to attract many large investors, and shares of AbbVie Inc will grow. Conversely, allegations of tax evasion negatively affect the company's image and, consequently, the stock price.
Global health statistics can also provide clues about the future value of ABBV. New diseases increase competition in the pharmaceutical market, and as a result, the volatility of stocks of drug manufacturers may increase. This is often used by intraday traders. Also, the movement of the rate can be prompted by the financial statements of AbbVie Inc. Positive data contributes to the rise of ABBV stock.
Risk warning: Trading in FX and CFDs entails high risk of losing capital.
Are you interested in buying AbbVie Inc (#ABBV)? It’s easy!
SellBuyActive SellActive Buy
| Sell | 196.33 |
| Buy | 196.43 |
| Sentiment | 69.0% ▾ |
| 1-day change | 8.4(4.47%) |
Earn from the fluctuations of prices and boost your income with LiteFinance!
#ABBV (#ABBV) shares’ cost is $196.43 for today. The highest rate of shares #ABBV (#ABBV) for today is $196.5000, the lowest price is $194.1700. The opening price was $195.25.
A real-time chart for #ABBV (#ABBV) shares quote is provided below.
Price chart of #ABBV in real time mode
Available in trading accounts:
- ECN
- CLASSIC
Prev. Close195.18
Day's Range194.1700 - 196.5000
Opening195.25
52 wk Range135.85-198.3
Volume3,820,802
Shares Outstanding1,766,343,745
Average Volume5,365,540
Market Cap346.75B
1-Year Return32.46%
EPS3
Beta0.623
Revenue55B
P/E Ratio64.99
Dividends6.20(3.16%)
Next Earnings Date2024-10-25
Spread0
Swap Long-6
Contract size1
Swap Short2.5
Stop&Limit Level0
| #AA | N/A | N/A | -0.42 | -1.29% |
| #ABBV | N/A | N/A | 8.4 | 4.47% |
| #ABT | N/A | N/A | 6.45 | 6.04% |
| #ADM | N/A | N/A | -0.71 | -1.15% |
| #AMWL | N/A | N/A | -2.03 | -19.77% |
| #AXP | N/A | N/A | 6.6 | 2.62% |
| #BA | N/A | N/A | -11.02 | -5.98% |
| #BABA | N/A | N/A | 4.04 | 5.10% |
| #BAC | N/A | N/A | 1.1 | 2.77% |
| #BB | N/A | N/A | -0.07 | -2.90% |
| #CAT | N/A | N/A | 11.36 | 3.30% |
| #CLX | N/A | N/A | 27.22 | 20.76% |
| #COTY | N/A | N/A | -0.48 | -4.87% |
| #CVX | N/A | N/A | -8.8 | -5.62% |
| #DIS | N/A | N/A | -3.11 | -3.33% |
| #DVN | N/A | N/A | -1.68 | -3.61% |
| #EDU | N/A | N/A | -0.05 | -0.08% |
| #F | N/A | N/A | 0.34 | 3.13% |
| #FIS | N/A | N/A | 6.07 | 7.95% |
| #FTI | N/A | N/A | -2.65 | -8.99% |
| #GD | N/A | N/A | 3.23 | 1.09% |
| #GE | N/A | N/A | 0.56 | 0.32% |
| #GPN | N/A | N/A | 10.02 | 9.94% |
| #HD | N/A | N/A | 1.11 | 0.30% |
| #HPQ | N/A | N/A | 0.12 | 0.33% |
| #IBM | N/A | N/A | 10.16 | 5.29% |
| #JNJ | N/A | N/A | 7.63 | 4.82% |
| #JPM | N/A | N/A | 14.05 | 6.67% |
| #KMI | N/A | N/A | 0.54 | 2.57% |
| #KO | N/A | N/A | 5.73 | 8.59% |
| #KODK | N/A | N/A | -0.49 | -8.51% |
| #LMT | N/A | N/A | 26.68 | 4.93% |
| #MA | N/A | N/A | 18.68 | 4.02% |
| #MCD | N/A | N/A | 25.11 | 9.53% |
| #MLM | N/A | N/A | -55.64 | -9.44% |
| #MMM | N/A | N/A | 8.5 | 6.73% |
| #MO | N/A | N/A | 4.3 | 8.69% |
| #MS | N/A | N/A | 0.79 | 0.77% |
| #NIO | N/A | N/A | -0.24 | -5.61% |
| #NSC | N/A | N/A | 7.85 | 3.16% |
| #OXY | N/A | N/A | -3.23 | -5.37% |
| #PFE | N/A | N/A | -1.24 | -4.10% |
| #PG | N/A | N/A | 10.45 | 6.49% |
| #PM | N/A | N/A | 8 | 6.94% |
| #RNG | N/A | N/A | -1.28 | -3.71% |
| #RTX | N/A | N/A | 6.62 | 5.67% |
| #SLB | N/A | N/A | -3.5 | -7.37% |
| #SNOW | N/A | N/A | -13.68 | -10.73% |
| #SQ | N/A | N/A | 2.79 | 4.41% |
| #STZ | N/A | N/A | -5.06 | -2.06% |
| #T | N/A | N/A | 0.74 | 3.86% |
| #TAP | N/A | N/A | 1.08 | 2.05% |
| #TME | N/A | N/A | -3.5 | -25.18% |
| #TOT | N/A | N/A | 1.61 | 2.39% |
| #V | N/A | N/A | 11.28 | 4.26% |
| #VMC | N/A | N/A | -28.04 | -10.29% |
| #VZ | N/A | N/A | 1.46 | 3.62% |
| #WMT | N/A | N/A | 8.17 | 11.83% |
| #XOM | N/A | N/A | -0.75 | -0.63% |
| #NFLX | N/A | N/A | 58.67 | 9.14% |
| #NKE | N/A | N/A | N/A | N/A |
Interesting facts about the #ABBV (AbbVie Inc)
As we have mentioned above, the company was founded in 2013. Only a year later, in 2014, AbbVie collaborated with Calico to research and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer.
Since the end of 2014, the company’s medicines for various diseases have been approved by the US FDA. It is always an important factor when you consider companies to invest in or trade stocks. The approval of medicine is always an issue for biopharmaceutical companies, as any delay in the approval may lead to a loss of billions of dollars and a fall in the stock price.
In 2016, AbbVie opened the Cambridge Research Center. As a result, it expanded its neuroscience research areas, including Alzheimer’s Disease.
The company has been among the leaders of the Dow Jones Sustainability Index for many years in a row.
Over the years, the company has been recognized in many lists of leaders in various areas. For instance, AbbVie was included in:
- The Barron's 500 ranking (which included the 500 largest companies by sales in the previous fiscal year with a primary stock listing in the US or Canada)
- Reputation Institute Global Pharma RepTrak
- Fortune’s list of the 100 best companies to work for.
Over the recent years, the company’s earnings and revenue have been growing faster than the US drug manufacturers industry average. Moreover, the company has been demonstrating solid long-term earnings growth for several years.
Still, traders should be careful, as the company’s competitors may outperform it. This may lead to a decline in the share price. AbbVie’s key rivals are Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche, and Johnson & Johnson.
AbbVie’s stock is listed on the New York Stock Exchange under the #ABBV symbol. The company is a part of such world indices as S&P 500, DJ US, DJ Large-Cap, and DJ Health Care.
Follow us in social networks!
Live Chat
Leave a feedback